// App-Quantinova.ai

: Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Noel W. Clarke

Principal Investigators

  • Antoine Thiery-Vuillemin

  • Mototsugu Oya

  • Neal D. Shore

  • Giuseppe Procopio

  • João Daniel Cardoso Guedes

  • Cagatay Arslan

  • Niven Mehra

  • Francis Parnis

  • Emma Brown

  • Friederike Schlürmann

  • Jae Young Joung

  • Mikio Sugimoto

  • A. Oliver Sartor

  • Yu-Zhen Liu

  • Christian Heinrich Poehlein

  • Laura Barker

  • Paula Michelle del Rosario

  • Fred Saad

Medical Centers

  • Centre Hospitalier de Cornouaille, Quimper, France

  • Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC

  • Kanazawa University, Kanazawa, Japan

  • University of Southampton, Southampten, United Kingdom

  • Radboud University Medical Center, Njmegen, Netherlands

  • Global Medical Development Oncology, AstraZeneca, Cambridge, United Kingdom

  • CHRU Besançon Hôpital J.Minjoz, Besançon, France

  • İzmir Economy University Medical Park Hospital, Karsiyaka, Turkey

  • Centre Hospitalier de lUniversite de Montreal/CRCHUM, University of Montreal, Montreal, QC, Canada

  • Tulane Cancer Center, New Orleans, LA

  • Ashford Cancer Centre Research, Kurralta Park, SA, Australia

  • Hospital de Base de Sao Jose do Rio Preto, Sao Jose Do Rio Preto/SP, Brazil

  • National Cancer Center, Goyang-si, Korea

  • Istituto Nazionale Tumori, Milano, Italy

  • The Christie and Salford Royal NHS Foundation Trusts, Manchester, United Kingdom

  • The Jikei University School of Medicine, Tokyo, Japan

  • Carolina Urologic Research Center, Myrtle Beach, SC

Locations

  • Netherlands

  • Republic of South Korea

  • Italy

  • Turkey

  • France

  • Canada

  • Japan

  • Australia

  • United Kingdom

  • Brazil

  • United States

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating DNA

Drug/Treatment

  • Prednisolone

  • CB-7598

  • Prednisone

  • Olaparib

  • Propel

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT03732820

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved